NUR 210 | PRINCIPLES OF
PHARMACOLOGY | EXAM 1 STUDY
GUIDE 2026 QUESTIONS AND ANSWERS
1. Which pharmacokinetic process is primarily affected by the ‘first-pass effect’ when a drug
is administered orally?
A. Distribution
B. Metabolism
C. Excretion
D. Absorption
Answer: B
Conceptual Explanation: The first-pass effect refers to the metabolism of a drug by the
liver after it is absorbed from the gastrointestinal tract and before it reaches the systemic
circulation.
2. A patient with low serum albumin levels is at risk for drug toxicity when taking highly
protein-bound medications. What is the physiological rationale?
A. The drug is metabolized faster by the liver.
B. More free drug is available to reach target tissues.
,C. The kidneys excrete the drug more efficiently.
D. The drug remains trapped in the vascular space.
Answer: B
Conceptual Explanation: Only ‘free’ or unbound drug molecules can leave the vascular
space and exert a pharmacological effect; low albumin means more drug remains unbound
and active.
3. Which of the following describes a ‘prodrug’?
A. A drug that bypasses the liver entirely.
B. An inactive compound that becomes active after metabolism.
C. A drug that is excreted without being metabolized.
D. A drug that has reached its steady-state concentration.
Answer: B
Conceptual Explanation: Prodrugs require metabolic conversion (usually by the liver) to
become pharmacologically active.
4. In which phase of the FDA drug approval process is the drug tested on a small number of
healthy volunteers to determine its pharmacokinetics?
A. Phase III
B. Phase II
C. Phase I
, D. Phase IV
Answer: C
Conceptual Explanation: Phase I trials focus on safety, dosage ranges, and
pharmacokinetics in a small group of healthy volunteers.
5. A drug has a half-life of 4 hours. If a patient takes a 200mg dose, how much drug remains in
the body after 12 hours?
A. 100 mg
B. 25 mg
C. 50 mg
D. 12.5 mg
Answer: B
Conceptual Explanation: After 4 hours (1 half-life), 100mg remains; after 8 hours (2 half-
lives), 50mg remains; after 12 hours (3 half-lives), 25mg remains.
6. What does a ‘Narrow Therapeutic Index’ (NTI) indicate about a medication?
A. The drug is highly effective at low doses.
B. The drug has a high margin of safety.
C. The drug does not require therapeutic drug monitoring.
D. Small differences in dose or blood concentration may lead to serious therapeutic failures
or adverse reactions.
PHARMACOLOGY | EXAM 1 STUDY
GUIDE 2026 QUESTIONS AND ANSWERS
1. Which pharmacokinetic process is primarily affected by the ‘first-pass effect’ when a drug
is administered orally?
A. Distribution
B. Metabolism
C. Excretion
D. Absorption
Answer: B
Conceptual Explanation: The first-pass effect refers to the metabolism of a drug by the
liver after it is absorbed from the gastrointestinal tract and before it reaches the systemic
circulation.
2. A patient with low serum albumin levels is at risk for drug toxicity when taking highly
protein-bound medications. What is the physiological rationale?
A. The drug is metabolized faster by the liver.
B. More free drug is available to reach target tissues.
,C. The kidneys excrete the drug more efficiently.
D. The drug remains trapped in the vascular space.
Answer: B
Conceptual Explanation: Only ‘free’ or unbound drug molecules can leave the vascular
space and exert a pharmacological effect; low albumin means more drug remains unbound
and active.
3. Which of the following describes a ‘prodrug’?
A. A drug that bypasses the liver entirely.
B. An inactive compound that becomes active after metabolism.
C. A drug that is excreted without being metabolized.
D. A drug that has reached its steady-state concentration.
Answer: B
Conceptual Explanation: Prodrugs require metabolic conversion (usually by the liver) to
become pharmacologically active.
4. In which phase of the FDA drug approval process is the drug tested on a small number of
healthy volunteers to determine its pharmacokinetics?
A. Phase III
B. Phase II
C. Phase I
, D. Phase IV
Answer: C
Conceptual Explanation: Phase I trials focus on safety, dosage ranges, and
pharmacokinetics in a small group of healthy volunteers.
5. A drug has a half-life of 4 hours. If a patient takes a 200mg dose, how much drug remains in
the body after 12 hours?
A. 100 mg
B. 25 mg
C. 50 mg
D. 12.5 mg
Answer: B
Conceptual Explanation: After 4 hours (1 half-life), 100mg remains; after 8 hours (2 half-
lives), 50mg remains; after 12 hours (3 half-lives), 25mg remains.
6. What does a ‘Narrow Therapeutic Index’ (NTI) indicate about a medication?
A. The drug is highly effective at low doses.
B. The drug has a high margin of safety.
C. The drug does not require therapeutic drug monitoring.
D. Small differences in dose or blood concentration may lead to serious therapeutic failures
or adverse reactions.
